ApcinteX

The company's core product is SerpinPC, an inhibitor of activated protein C (APC). This biologic is designed to rebalance coagulation in haemophilia patients by allowing more thrombin to be generated. A key feature of SerpinPC is its potential to treat all types of haemophilia, regardless of severity or the patient's inhibitor status, with a convenient subcutaneous injection. This approach contrasts with standard treatments that require regular intravenous infusions of missing coagulation factors and can be rendered ineffective if patients develop inhibitory antibodies.

In its early stages, ApcinteX secured a Series A funding round of approximately $17.5 million, with investors including Medicxi, Touchstone Innovations, and IP Group. The company began clinical trials for SerpinPC in 2019, with a Phase I/II study to assess its safety and tolerability in healthy volunteers and haemophilia patients. By February 2021, ApcinteX was acquired by Centessa Pharmaceuticals as part of a larger merger involving ten biotech companies. The acquisition was part of Centessa's launch with a $250 million Series A financing round. Following the acquisition, ApcinteX operates as a subsidiary of Centessa, continuing the development of SerpinPC.